Anacor Pharmaceuticals Director Unloads $294,008 in Stock (ANAC)
Anacor Pharmaceuticals (NASDAQ:ANAC) Director Mark Leschly sold 13,067 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $22.50, for a total transaction of $294,007.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at Jefferies Group raised their price target on shares of Anacor Pharmaceuticals from $24.00 to $25.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $24.50.
Anacor Pharmaceuticals (NASDAQ:ANAC) traded up 2.78% during mid-day trading on Friday, hitting $23.29. 432,586 shares of the company’s stock traded hands. Anacor Pharmaceuticals has a 52 week low of $9.84 and a 52 week high of $23.09. The stock’s 50-day moving average is $18.46 and its 200-day moving average is $17.75. The company has a market cap of $978.1 million and a price-to-earnings ratio of 14.11.
Anacor Pharmaceuticals (NASDAQ:ANAC) last announced its earnings results on Thursday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.63) by $0.05. The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $3.03 million. During the same quarter last year, the company posted ($0.36) earnings per share. Anacor Pharmaceuticals’s revenue was down 14.7% compared to the same quarter last year. On average, analysts predict that Anacor Pharmaceuticals will post $-2.39 earnings per share for the current fiscal year.
Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.